2019 American Transplant Congress
Changes in the Fate of KDPI < 35% Kidneys before and after Implementation of the New Kidney Allocation System
Northwell Health, Manhasset, NY
*Purpose: Though the chances of long term graft survival are highest with low KDPI kidneys, there is concern that after implementation of the new kidney…2019 American Transplant Congress
A Safe Anti-A2 Titer for a Succesful A2 Incompatible Kidney Transplantation
Montefiore Medical Center, Bronx, NY
*Purpose: The new kidney allocation system implemented in December 2014 allowed for use of A2/A2B donors to B recipients. However there is no mandate by…2019 American Transplant Congress
Risk Factors for 1-5 Year Major Infection Events (MIE) after Kidney Transplant (KTx) Including First-Year Immunosuppression (IS) Data: An Analysis of the Choosing Immune Suppression in Renal Transplantation by Efficacy and Morbidity (CISTEM) Study
*Purpose: From our CISTEM study of linked national registries, we reported that older recipient age, female sex, diabetic kidney failure, non-standard-criteria organs, and mTORi-based IS…2019 American Transplant Congress
The End of Non-Directed Living Kidney Donation: The National Kidney Registry’s Family Voucher Program
*Purpose: The continued growth of the National Kidney Registry’s (NKR) Voucher program has extended Kidney Paired Donation (KPD) to include chronological incompatibility which is facilitating…2019 American Transplant Congress
Can Cardiac Risk Predictor Models Be Trusted in Kidney Transplant Recipients?
*Purpose: Kidney transplant recipients (KTR) bear a higher risk of developing cardiovascular disease due to comorbid conditions. Non-invasive cardiovascular risk stratification tools have not been…2019 American Transplant Congress
Optimal Timing of Hepatitis C Treatment among HIV/HCV Co-Infected End-Stage Renal Disease Patients: Pre vs. Post-Transplant
*Purpose: End-stage renal disease (ESRD) patients co-infected with HCV and HIV have access to effective treatment options for HCV infection. However, they also have access…2019 American Transplant Congress
CNI-Free Therapy with Iscalimab (anti-CD40 mAb) Preserves Allograft Histology Compared to Standard of Care after Kidney Transplantation
*Purpose: To assess if calcineurin (CNI)-free therapy with iscalimab preserves the quality of transplanted kidney grafts.*Methods: Iscalimab (CFZ533) is a new, fully human, Fc-silenced, non-depleting,…2019 American Transplant Congress
Comparison of Isolated Transplant Glomerulopathy with Chronic Antibody-Mediated Rejection in Regards to Endothelial-to-Mesenchymal Transition and Graft Survival
*Purpose: Transplant glomerulopathy (TG) has been proposed to be a component of chronic antibody-mediated rejection (CAMR). However, a substantial number of patients with TG do…2019 American Transplant Congress
Increase in Proinflammatory CD14++CD16+ Monocytes in Samples from Aspiration Cytology Compared with Peripheral Blood in Kidney Transplant Patients with Borderline Rejection
*Purpose: Monocytes comprise a heterogeneous population divided according to the membrane expression level of their molecules. One of these populations is the CD14++CD16+, which presents…2019 American Transplant Congress
Evaluation of Delayed Renal Allograft Function after DCD with New Biomarkers in Donor Blood
Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
*Purpose: To explore the relationship between new biomarkers in donor blood and delayed graft function (DGF) after DCD kidney transplantation, and to evaluate the clinical…
- « Previous Page
- 1
- …
- 236
- 237
- 238
- 239
- 240
- …
- 531
- Next Page »